Beam Therapeutics recently announced that its BEAM-302 program received FDA orphan drug designation, alongside encouraging updates for its gene-editing therapies targeting rare diseases such as sickle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback